 The FDA has signed off Intellia Therapeutics Incs NASDAQ: NTLA investigational new drug IND application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPRCas9 Genome Editing Candidate. 